Why the study?
Does rilonacept improve resolution and reduce recurrence of pericarditis in patients with recurrent pericarditis?
Does rilonacept improve resolution and reduce recurrence of pericarditis in patients with recurrent pericarditis?
Rilonacept provides rapid resolution and significantly lowers the risk of recurrence in patients with recurrent pericarditis compared to placebo.
Answers are grounded in this paper and cite their sources.
Rilonacept may be considered for recurrent pericarditis; confirms IL-1 blockade efficacy in this RCT.
Among patients with recurrent pericarditis, rilonacept led to rapid resolution of recurrent pericarditis episodes and to a significantly lower risk of pericarditis recurrence than placebo. (Funded by Kiniksa Pharmaceuticals; RHAPSODY ClinicalTrials.gov number, NCT03737110.).
No takes yet. Share an insight, caveat, or question.
Klein et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: